We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
ALR Technologies is a medical device company providing remote monitoring and care ...
ALR Technologies is a medical device company pr...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focu...
Paratek Pharmaceuticals, Inc. is a commercial-s...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
Join the National Investor Network and get the latest information with your interests in mind.